ArticleThe Lancet regional health. Western Pacific2026
HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sustained HBsAg seroclearance with HBV DNA suppression is associated with favorable outcomes in chronic hepatitis B (CHB), but its associations with overall survival and cause-specific mortality remain insufficiently quantified. Methods: In a prospective, multicenter, community-based cohort of 6018 Chinese CHB patients, sustained HBsAg seroclearance with HBV DNA <100 IU/mL was modeled as a time-dependent exposure using propensity score-matched Cox regression. We estimated population attributable fractions (PAFs) for burden associated with persistent infection and restricted mean survival time (RMST) for survival difference. Findings: During a median 11.1-year follow-up, 1029 participants with sustained HBsAg seroclearance and HBV DNA <100 IU/mL (97.0% spontaneously) were compared with 2931 matched participants with persistent infection. This serovirological state was associated with lower risks of cirrhosis (adjusted hazard ratio [aHR], 0.45; 95% CI, 0.27-0.74) and hepatocellular carcinoma (aHR, 0.52; 95% CI, 0.33-0.81). It was also associated with lower all-cause mortality (aHR, 0.47; 95% CI, 0.36-0.60), as well as liver-related, extrahepatic cancer-related, and cardiovascular mortality. The RMST difference was 5.17 years within the observed age range. Interpretation: Sustained HBsAg seroclearance accompanied by very low HBV DNA levels was associated with lower risks of adverse liver outcomes and selected extrahepatic mortality, as well as longer RMST, highlighting the prognostic relevance of this serovirological state for long-term risk stratification in CHB. Funding: National Natural Science Foundation of China (82373654, 82674792); Jiangsu Provincial Key Discipline of Epidemiology (ZDXK202250); Scientific Research Project of Jiangsu Provincial Health Commission (H2023041); Science and Technology Plan Project of Jiangsu Provincial Disease Control and Prevention Administration (JSJK2026M00015).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.